Arkadios Wealth Advisors Acquires Shares of 20,000 Autolus Therapeutics plc (NASDAQ:AUTL)

Arkadios Wealth Advisors acquired a new stake in Autolus Therapeutics plc (NASDAQ:AUTL) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $47,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Avanza Fonder AB acquired a new position in shares of Autolus Therapeutics in the fourth quarter valued at $75,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $611,000. JPMorgan Chase & Co. boosted its position in shares of Autolus Therapeutics by 145.3% in the third quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock valued at $4,663,000 after acquiring an additional 761,008 shares during the period. Wellington Management Group LLP boosted its position in shares of Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after acquiring an additional 6,330,392 shares during the period. Finally, State Street Corp boosted its position in shares of Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after acquiring an additional 10,401 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Friday, November 15th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Up 3.5 %

AUTL opened at $2.37 on Friday. Autolus Therapeutics plc has a twelve month low of $2.07 and a twelve month high of $7.37. The company has a 50-day simple moving average of $2.60 and a 200 day simple moving average of $3.51. The stock has a market capitalization of $630.63 million, a price-to-earnings ratio of -1.96 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the company earned ($0.26) EPS. Sell-side analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.